Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00599820
First received: June 30, 2006
Last updated: January 23, 2008
Last verified: January 2008

June 30, 2006
January 23, 2008
November 2005
Not Provided
  • BCVA
  • Fluoresceine Angiography
  • Optical Coherence Tomography
Same as current
Complete list of historical versions of study NCT00599820 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Angioid Streaks
  • Choroidal Neovascularization
Drug: Intravitreal Bevacizumab
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
May 2006
Not Provided

Inclusion Criteria:

  • Clinical diagnosis of Angioid Streaks
  • Choroidal neovascularization associated
  • Untreated patients or patients treated once with PDT

Exclusion Criteria:

  • Ocular surgery excepting uncomplicated phacoemulsification
  • Glaucoma or any other ocular pathology
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
NCT00599820
APEC 010
Not Provided
Not Provided
Asociación para Evitar la Ceguera en México
Not Provided
Principal Investigator: Adriana Solís-Vivanco, MD Asociación para Evitar la Ceguera en México
Study Chair: Jans Fromow-Guerra, MD PhD Asociación para Evitar la Ceguera en México
Study Chair: Mariana Martínez-Castellanos, MD Asociación para Evitar la Ceguera en México
Study Chair: Elizabeth Reyna-Castelán, MD Asociación para Evitar la Ceguera en México
Study Chair: Myriam Hernández-Rojas, MD Asociación para Evitar la Ceguera en México
Study Chair: Griselda Alvarez-Rivera, MD Asociación para Evitar la Ceguera en México
Study Director: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en México
Asociación para Evitar la Ceguera en México
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP